SLC5A2 and diabetic kidney disease: Weekly administration of FMD once a month over a period of six months has already been shown to significantly reduce albuminuria and improve glycemic control in individuals with T2D and diabetic nephropathy, showing a comparable effect size as reported from interventions with SGLT2-inhibitors (19, 32).